Introduction
Our last review pertaining to mucosa-associated lymphoid tissue (MALT) lymphoma was published over 10 years ago [1] . We thus deemed it appropriate to provide an update in view of the recent advances that have since been made on this topic, thereby covering disease pathophysiology, diagnostic approaches, and novel treatments. B-cell lymphoma may occur in the lungs as secondary localization originating from extra-pulmonary lymphomas. T-cell lymphomas, however, are uncommon. Primary pulmonary lymphoma (PPL) is defined as a clonal lymphoid proliferation affecting parenchyma and/or bronchi of one or both lungs, with no detectable extra-pulmonary involvement at diagnosis or during the subsequent 3 months [2, 3] . PPL presents clinically in several different ways, each associated with a distinct B-cell lymphoma histological subtype. The most common PPL types are, in order of decreasing frequency [2, 4] : (1) extranodal marginal zone lymphoma (MZL) of MALT lymphoma, (2) diffuse large B-cell lymphoma (DLBCL), and (3) lymphomatoid granulomatosis (LG).
This general review sought to focus on and clarify the pathophysiological, diagnostic, prognostic, and therapeutic features of pulmonary MALT lymphoma.
Terminology
MALT lymphoma is the most common type of indolent B-cell PPL [5] (Table I) , originating from post-germinal centre memory B-cells. They belong to the group of marginal zone B-cell lymphomas (MZLs) which also includes nodal and splenic MZL. However, these 3 MZL subtypes present very distinct clinical, morphological and molecular features [6] [7] [8] [9] [10] . MALT lymphomas represent 8% of adults diagnosed cases of non-Hodgkin lymphoma (NHLs) [11] , making them the fourth most common histological subtype after DLBCL, follicular lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma [5] .
From MALT to MALT lymphoma
MALT lymphomas rarely occur at sites where MALT is physiologically abundant, the Peyer's patches of the terminal ileum, most frequently found rather at sites usually devoid of MALT, such as the stomach, salivary glands, lungs, and thyroid.
Marginal zone (MZ) and bronchial mucosa-associated lymphoid tissue
The histological features of the marginal zone (MZ) of lymphoid follicles was first described in the spleen [12] , later recognized in other sites, such as the Peyer's patches and in lymph nodes. Functionally, MZ B-lymphocytes are memory B-cells, and are involved in T-celldependent or -independent immune responses. MALT is a lymphoid tissue specialized in defending the mucosa [2] , first described in the gastrointestinal tract (GALT) in animal models, then later in the ileum in humans. MALT is composed of four compartments: (1) organized mucosal lymphoid tissue, that consists of reactive lymphoid follicles which forms Peyer's patches when concentrated in the terminal ileum; (2) the lamina propria; (3) intraepithelial lymphocytes; (4) the mesenteric lymph nodes ( Figure 1 ) [2] .
Peyer's patches are mucosal non-encapsulated aggregates of lymphoid tissue, the structure of which is similar to that of nodal lymphoid follicles. The MZ surrounds the mantle zone of the follicle and extends toward the mucosal surface. It is composed of centrocyte-like cells, which resemble monocytoid cells and express pan B antigens, surface IgM, and surface IgA1, whereas being negative for surface IgD, CD5, and CD10. This differentiates them from naive Bronchus-associated lymphoid tissue (BALT) was first described in fetal and neonatal lungs affected by pulmonary infections of undetermined nature [2] . BALT can also be found in follicular bronchiolitis and be associated with various autoimmune disorders, such as Sjögren's syndrome, yet is not found in normal lungs. The stomach is the most commonlyaffected organ in terms of MALT lymphoma, and several features of stomach MALT lymphoma can be extrapolated to MALT lymphoma in other locations like the lungs.
MALT chronic antigen stimulation
Lymphomas of the MZ are generally associated with chronic antigen stimulation, regardless of whether the antigens are auto-antigens or of microbial origin ( Figure 2 ) [12] . This is an unusual form of lymphoproliferation, in which the infectious agent does not infect or directly transform the lymphoid cells, unlike lymphomas associated with Epstein-Barr virus (EBV), human herpesvirus 8 (HHV8), or human T-cell leukemia virus 1 (HTLV1) [13] . In MZ lymphomas, the infectious agent increases the risk of lymphomatous transformation by chronically stimulating B-lymphocyte proliferation. In cases of chronic antigen stimulation, such as helicobacter pylori (H. pylori) infection, MALT develops in the stomach and can later undergo lymphomatous transformation starting with the B-lymphocytes in the MZ. In the original observation of gastric MALT lymphoma, the malignant B-cell clone process initially requires the presence of the H. pylori antigen in order to proliferate, H. pylori being detected in almost 90% of gastric biopsies from patients with gastric MALT lymphoma [14, 15] , and its eradication leads to complete and prolonged disease remission in 60-80% of early-stage gastric MALT lymphoma cases. H. pylori eradication has also been reported to be effective in localized gastric DLBCL [12, 14, 16] . However some recent studies show an increasing rate of H. pylori -negative patients of up to 30-50% of gastric MALT lymphoma [17] . The reason for this remains unclear; the liberal use of antibiotic in patient with suspected H. pylori infection or symptoms might be a potential explanation for a shift in MALT lymphoma characteristics in the near future.
Other infectious agents have been suggested as possible causes of MALT lymphoma at other sites [12, 18, 19] . A causal relationship has been suggested between Campylobacter jejuni infection and small intestine MALT lymphoma, formerly known as alpha-chain disease or MALT lymphoma (n=69). The results were compared to control specimens of other pulmonary lymphoproliferative disorders (n=30) and non-lymphoproliferative disorders (n=44) [20] . In this study, chlamydiaceae DNA was detected more frequently in MALT tissue than in samples taken from patients with non-lymphoproliferative disorders, although the difference was not statistically significant. Mycoplasma DNA was not detected. In addition, a recent multicentric European study using a 16S ribosomal ribonucleic acid (RNA)-based approach found DNA from Achromobacter xylosoxidans in 57/124 pulmonary MALT lymphomas vs. 15/82 controls (p=0.004) [21] . Further studies are now required to prove the causal relationship between this pathogen and pulmonary MALT lymphoma. Using a non-a priori approach, our team assiduously pursues its research in this field using modern microbiology techniques. Powerful tools have, in fact, been developed for both DNA and RNA sequencing [22] , enabling the analysis of all DNA and RNA present in a given sample, which could provide some evidence of a specific pathogen's presence be associated with pulmonary MALT lymphoma [23] .
Chronic antigen stimulation may also be of autoimmune origin (Figure 2 ). MALT lymphomas in the salivary and thyroid glands have been more commonly observed in patients with autoimmune disease, Sjögren's syndrome or Hashimoto's thyroiditis, respectively. A metaanalysis involving 29,423 patients [24] confirmed that those with Sjögren's syndrome or systemic lupus erythematosus exhibited increased risk of MZ lymphoma. Primary or secondary Sjögren's syndrome was reported to be associated with a 6.5-fold increased risk of any type of lymphoma, a 1000-fold increased risk of salivary gland MALT lymphoma, and a 5-fold increased risk of lymphoma at other extranodal sites. Systemic lupus erythematosus was associated with a 2.7-fold increased risk of any type of lymphoma, and a 12.9-fold increased risk of extranodal lymphoma. Disorders involving chronic antigen stimulation, such as systemic lupus erythematosus, multiple sclerosis, Hashimoto's thyroiditis, and, in particular, Sjögren's syndrome, are all recognized risk factors for developing pulmonary MALT lymphoma [24] .
Due to environmental risk factors, bakers and oil workers display an increased risk of ocular adnexal and cutaneous MALT lymphoma lymphomas, respectively [25] . However this risk
has not yet been evidenced in pulmonary MALT lymphomas.
Cytogenetic abnormalities
The cytogenetic abnormalities that characterize and promote MALT lymphomas have been known for several years (Table II, Figure 2 ). Both the frequency and type of cytogenetic abnormality vary depending on the lymphoma's site, and may also be related to the patient's origin. As opposed to other forms of lymphoma, MALT lymphomas are not characterized by a diagnostic genetic aberration, with the exception being to some extent t(11;18)(q21;q21) (API2-MALT1) discussed below, but rather display a variety of genetic features. Cytogenetic abnormalities are most frequently found in the lungs, and translocations are the most common abnormality type, with t(11;18)(q21;q21) being the most common translocation found and specific to MALT lymphomas [26] . This translocation is detected in 42% of pulmonary cases, 22% of gastric cases, and 15% of intestinal cases, though absent in most cases of thyroid, salivary gland, and liver MALT lymphoma [27, 28] . In gastric MALT lymphoma, the t(11;18) (q21;q21) translocation has been associated with lymph node dissemination and resistance to H. pylori-targeting antibiotics. As a consequence of this, the API2 gene (apoptosis inhibitor 2), located on chromosome 11, fuses with the MALT1 gene (MALT lymphoma-associated translocation), located on chromosome 18, resulting in the production of a chimeric protein: AP12-MALT1. Other translocations include the t(1;14)(p22;q32)/IGH-BCL10, t(14;18)(q32;q21) (IGH-MALT1), two rarer translocations reported in the stomach, lung and skin for the t(1;14) and in the liver, lung and ocular adnexa for the t(14;18) [27] . In each case, the translocation results in transcriptional dysregulation of the modified gene, and overexpression of BCL10 and MALT1, respectively in tumors cells. Another translocation, t(3;14)(p14.1;q32)(FOXP1-IGH), has recently been described, but is not specific of MALT lymphomas since it has also been reported in diffuse large B-cell lymphomas. Its presence excludes t(11;18)(q21;q21). FOXP1 protein is also overexpressed in MALT lymphomas with trisomy 3, suggesting that increased gene copy number may be another mechanism of deregulated gene expression.
All the translocations listed above, with the exception of t(3;14)(p14.1;q32), result in the constitutive activation of the NF-κB signaling pathway. The above-mentioned translocations can be detected detected either by interphase fluorescent in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) tissue sections or alternatively by reversetranscriptase PCR assays (RT-PCR) in frozen tumor samples [24] [26] . Other cytogenetic abnormalities associated with MALT lymphoma are trisomy 3 and 18 [26] . Aneuploidy is rarely associated with t(11;18).
Finally, MALT lymphoma could develop as a result of both cytogenetic abnormalities and antigenic stimulation. Illustrating this point, a mouse model simulating bcl10 or API2-MALT overexpression demonstrated the development of marginal zone hyperplasia without lymphoma. On the other hand, the mice undergoing API2-MALT1 overexpression developed lymphoma following antigenic stimulation with Freund adjuvant [29] [30] [31] .
Epidemiology, clinical tests, and imaging
PPLs are rare clinical entities, representing only 0.5-1% of lung neoplasia cases ( Figure 3 ).
MALT lymphomas represent over 80% of PPL cases, constituting the most common type of pulmonary lymphoma [32] [33] [34] . PPL onset usually occurs at around 50-60 years of age, very occasionally affecting those under 30 years old [1] . Smoking rates (≈35%) were not found to be no higher among people that develop PPL than in the general population [34] , and women were affected just as often as men. The presence of an immune system disorder was identified to be a predisposing factor for developing a MALT lymphoma, with a recent study reporting that 16% of patients presented an autoimmune disease at the time of diagnosis [34] .
In nearly half of MALT lymphoma cases the patients are asymptomatic at diagnosis, and investigations are initiated solely due to an abnormal chest X-ray. If symptoms are present, they are mostly nonspecific, commonly including cough, minimal dyspnea, and chest pain, with hemoptysis also sometimes reported. Crepitant rales are detected by pulmonary auscultation in less than 20% of cases. While general symptoms like fever and weight loss are observed in less than a quarter of MALT lymphoma patients, these are particularly associated with aggressive disease forms [1] .
On radiological examination, MALT lymphomas typically manifest as a chronic alveolar localized opacity, less than 5cm in diameter, and associated with air bronchogram in nearly 50% of cases [35] [36] [37] [38] [39] . Computed tomography (CT) (Figure 4) , which is more sensitive than standard X-ray, has demonstrated that the majority of MALT lesions are bilateral (60-70% of cases), multiple (70-77% of cases) [40, 41] , and contain a clear patch within each lesion, corresponding to the intact bronchial lumen. MALT lymphomas are often diagnosed based on the presence of distended bronchi within lesions [41] , and in less than 10% of cases, there are diffuse reticulonodular opacities in both lungs, atelectasis or pleural effusion [35] [36] [37] . Hilar or mediastinal lymphadenopathy may also be found on CT scan [35] . The mean time between the initial abnormal clinical or radiological findings and diagnosis is 9 months, though this may vary widely from 15 days up to 8 years [34] [35] [36] [37] [38] .
On the clinical level, the challenge is to correctly diagnose MALT lymphoma based on radiological findings of chronic diffuse or localized alveolar opacities, which can correspond to several different etiologies (Table III) .
Diagnostic approach
In cases where patients present with pulmonary lesions and when a MALT lymphoma is suspected, several approaches may be required to obtain sufficient information for a correct diagnosis, in order to exclude other inflammatory conditions and malignancies as well as accurately classify the exact lymphoma subtype. Tissue biopsy is the gold standard for diagnosis. FFPE biopsy samples are used for histological assessment and immunohistochemistry, while frozen samples are employed for molecular genetic analysis (PCR for immunoglobulin gene rearrangements). Biopsy samples can also provide cells for cytological examination and flow cytometry. The goal of the diagnostic approach is to use minimally-invasive techniques, such as bronchoscopy and CT-guided needle biopsy, in order to limit the number of invasive procedures, such as thoracotomy with surgical biopsies.
Contribution of bronchoscopy with biopsies and bronchioloalveolar lavage
While the macroscopic findings on bronchoscopy are usually normal [35] , abnormalities like inflammatory mucosa and bronchial stenosis may be observed [35] . Polypoid endobronchial lesions are very rare and usually appoint towards a small-cell non-Hodgkin lymphoma.
Bronchial and transbronchial biopsies are more fruitful when carried out on endobronchial lesions or guided by the topography of abnormalities mapped by CT scanning [35] . The sensitivity of bronchial and transbronchial biopsies in detecting MALT lymphoma was reported to be 31 and 88%, respectively ( Figure 5 ) [34] .
Bronchioloalveolar lavage (BAL) performed during bronchoscopy may also aid in diagnosing chronic alveolar opacities. This technique can indicate the absence of tumor epithelial cells that are found in other malignancies, e.g., lepidic adenocarcinoma (formerly termed bronchioloalveolar carcinoma), or the presence of pathogens pointing towards a chronic infection. The presence of lymphocytic alveolitis can also be indicative of PPL [42] , though this lymphocytosis often presents a T-cell phenotype and does not appear to be specific to PPL, unless the B-lymphocyte level is greater than 10% [35, 42, 43] . Lymphocytes obtained by BAL may also include monocytoid, centrocyte-like or plasmacytoid cells. The diagnostic value of B-lymphocyte alveolitis is at its most significant, if the clonality can be demonstrated by illustrating the clonal rearrangement of immunoglobulin genes using either molecular biology techniques or light-chain restriction by flow cytometry [44] [45] [46] [47] [48] . Nevertheless, a negative result does not exclude a MALT lymphoma diagnosis. In a recent study, 84% of patients with MALT lymphoma (n=35) exhibited over 15% of lymphocytic alveolitis. Blymphocytes accounted for more than 10% of the alveolar lymphocytes in cases where phenotyping was available, and the B-cell clone was identified in 71% of cases [49] .
Moreover, the translocation t(11 :18)(q21 ;q21), specific to MALT lymphomas, can be evidenced in BAL [50] . This data confirms that BAL could represent a powerful diagnostic tool that is currently underemployed in clinical practice.
If no specific lesion is identified by bronchoscopy, CT-guided aspiration and biopsy must be considered, particularly appropriate for peripheral nodules or masses. The sensitivity of this test has been reported to be 80% ( Figure 5 ) [34] . Diagnostic surgery may then be performed 
Contribution of immunohistochemistry
Immunohistochemistry analysis of FFPE tissue sections is mandatory to confirm the diagnosis of MALT lymphoma and to exclude reactive follicular hyperplasia or secondary localization to the lung of a nodal B-cell lymphoma. Tumor cells express CD20 and CD79a B-cell antigens and expand along bronchovascular bundles and interlobular septa ( Figure 7) [33, 36, 38, 39, 51-54, 58]. They are CD5 negative which allows excluding the diagnosis of mantle cell lymphoma or chronic lymphocytic leukemia [46] . Residual lymphoid follicles may be highlighted with the staining of CD21+ CD23+ residual follicular dendritic cells [35, 45, 47] .
Small reactive T-lymphocytes (CD3) can also be detected within the parietal alveolar infiltrate and around the peribronchiolar nodules [52, 54] . Plasma cell differentiation is further explored with immunostaining with anti-kappa and anti-lambda antibodies, and is very useful to distinguish MALT lymphoma with monotypic plasma cells from a reactive plasma cell infiltrate. Morphology and immunohistochemistry allow ruling out the lung localization of mantle cell, follicular, lymphoplasmocytic or lymphocytic lymphomas [52, 54] . The proliferative index is usually low (Ki-67<10%). 
Contribution of molecular biology

Differential diagnosis
The primary challenge in terms of histology, particularly when using a small specimen, is to distinguish MALT lymphoma from (1) diffuse lymphoid hyperplasia and lymphocytic interstitial pneumonia (LIP); (2) follicular bronchiolitis and chronic aspecific inflammatory reaction, or (3) other low grade B-cell lymphomas as previously discussed and chronic non-specific inflammatory reaction [53, 60] . While lymphoepithelial lesions may be observed in reactive conditions, detecting an intraepithelial lymphocytic infiltrate with a dual CD20/CD43-positive phenotype is nonetheless a strong indicator of MALT lymphoma [53] .
Molecular based methods for B-cell clonality and interphase FISH are useful tools to distinguish reactive conditions from lymphoma. Lastly, a unique nodular presentation may correspond to plasma cell granuloma, inflammatory myofibroblastic tumor, or IgG4 syndrome.
Prognosis and treatment Pretherapeutic staging
Lymph node lymphoma with secondary dissemination to the lungs can be ruled out using CT scan with contrast medium injection of the chest, abdomen, and pelvis, with contrast injection (Table IV) . Bone marrow biopsy is not essential but may show MALT lymphoma dissemination in 13-30% cases ( Figure 3 ) [7, 34, [61] [62] [63] . Similarly, concomitant disease in other mucosa-associated lymphoid sites is present in 25-35% of cases [62] [63] [64] (Figure 3 ), being more frequently observed in nondigestive MALT lymphomas. In a recent study of 63
MALT lymphoma cases, approximately 50% exhibited extrapulmonary involvement, 33% stomach involvement, and 14% bone marrow involvement [34] . Other mucosal sites must also be assessed only if symptomatic patients, including the eyes, ears, nose, and throat, in addition to magnetic resonance imaging (MRI) or ultrasound of the salivary and lacrimal glands, if in doubt, and gastroscopy and colonoscopy. Some cases may require evaluating the small-bowel transit.
Positron emission tomography using 18-fluorodeoxyglucose (PET-FDG) has yet to be investigated in detail. Its sensitivity and specificity can vary depending on the organ under consideration. PET-FDG assessment of the stomach appears to be associated with high rates of false-negatives, achieving a sensitivity of between 50 and 89% [65] . When assessing pulmonary disease it produces better results, with a sensitivity of between 80 and 100% [66, 67] . PET-FDG cannot enable assessment of bone marrow involvement [34] , though can detect plasmacytic differentiation with higher sensitivity [68] .
The only laboratory tests that are useful in pretreatment screening are lactate dehydrogenase (LDH) levels, serum electrophoresis, and immunoelectrophoresis. Monoclonal gammapathy, which is present in 8 out of 10 IgM-type cases, is also found in 20-60% of MALT lymphoma cases. It is detected more frequently if plasmacytic differentiation is revealed [35, [37] [38] [39] and in extrapulmonary disease cases [34] . Finally, increased β2 microglobulin level appears to be an independent factor associated with poor prognosis [62] .
Prognostic factors
The prognosis for patients with MALT lymphomas is good, with overall 5-year survival rates surpassing 80% and a median survival of over 10 years [33-39, 51, 56, 62-64, 69] . MALT lymphoma patients actually benefit from longer overall survival than patients with nodal or spleen MZ lymphoma [7] . However, the survival of patients with MALT lymphoma has not been demonstrated to be equivalent to that of the general population [32, 56] . The median survival of patients exhibiting MALT lymphoma of the digestive tract does not differ from that of other sites, yet progression-free survival seems to be shorter for diseases at other sites, particularly the lungs [61] . A long period of monitoring is required in these cases, as almost 50% of patients experience disease recurrence, either in the same location or outside the thoracic region [35, 39, 51, 56, 58] , after >2 years following surgical resection.
The prognostic factors for MALT lymphomas have not yet been clearly demonstrated. None of the factors like gender, delay to diagnosis, symptom presence, whether the lesions were bilateral or not, extra-pulmonary involvement or medullar location offered prognostic power [34] . In a multivariate analysis including all disease sites, elevated ß2 microglobulin levels [62] , and Stage IV classification according to the Ann Arbor system [70] were found to influence prognosis. In a study of 63 patients with pulmonary MALT lymphoma, age and performance status were poor prognostic factors for overall survival [34] . A further retrospective study involving 48 MALT lymphoma patients failed to identify any prognostic factors at all [71] . In a retrospective cohort of lymphoma associated with Sjögren syndrome, active Sjögren syndrome was associated with worse prognosis. However, this cohort included both MALT lymphoma and DLBCL cases [72] . Very recently Thieblemont and al. had
proposed a simple and effective prognosis factor including only age>70, Ann Arbor stage>2 and elevated LDH [73] . In a cohort of 393 patients, this 3 factors, when added, discriminated 3 risk groups with different 5-year progression free survival (78%, 63% and 29%; p < 0.001),
and 5-year overall survival (99%, 92% and 74%, p < 0.001).
The transformation of MALT lymphoma to DLBCL has been suggested by the fact that the two histological subtypes could be observed on sequential biopsies in one single patient, with similar rearrangements of the IGH genes and accumulation of genetic abnormalities [27, 33, 37, 39, 52, 54, 74] . Nevertheless, given the t(11:18) presence, a more aggressive treatment strategy could be justified [75] .
Main therapeutic options
The most recent recommendations have been centered on more frequent gastric MALT lymphoma [76, 77] . No microorganism has been identified that plays an equivalent role to H. pylori in gastric lymphoma. We are thus unable to use effective antibiotic treatment for pulmonary MALT lymphoma. However, a partial response has recently been reported in a patient with pulmonary MALT lymphoma, undergoing four courses of 14 days of clarithromycin (2g/d) without any pathogen evidenced [78] .
Current treatments include surgery, chemotherapy, immunotherapy and radiotherapy. It is not possible to assess the relative effectiveness of these treatments, as comparative groups do not exist, and even non-treatment could be considered [79] . Nevertheless, surgical resection or radiotherapy may be considered if the lesion is localized [35, 37, 80] . Radiotherapy may then offer the benefit of less morbidity [81, 82] .
The use of chemotherapy alone is permitted in cases of bilateral or extra-pulmonary disease, or in cases of disease recurrence or progression. Multiple-agent chemotherapy treatment, such as CHOP, is not thought to be superior to single-agent chemotherapy treatment using either chloraminophen or fludarabin [34, 35] . Furthermore, cyclophosphamide-or anthracyclinebased chemotherapy in comparison to chloraminophen were poor prognostic factors for progression-free survival in one study [34] . Anti-CD20 monoclonal antibodies (rituximab) are effective, producing a 70% response rate in MALT lymphoma irrespective of the disease site, yet they are associated with high disease recurrence rates (36%) [83] .
A prospective Phase III study involved 231 patients not suitable for local therapy, initiating them on a course of rituximab or rituximab-chloraminophen [84] . The primary objective was achieved, with significantly better 5-year event-free survival rates observed in the doubletherapy group compared to the monotherapy (68% vs. 50%, p=0.02). Double-therapy increased the complete response rate (78% vs. 65%). The 5-year progression-free survival rate was increased in the double-therapy group, although not significantly [84] . The 5-year survival was not improved (89% rate). Grade 3-4 neutropenia was more common in the double-therapy group, whereas infection and toxic-death rates were equivalent in both.
Rituximab alone was also evaluated in a third arm that was secondarly opened, the results of which being expected. In a retrospective cohort of gastric MALT lymphoma, the remission rate was 100% at 6 weeks when applying double-therapy, versus 45% with rituximab alone [75] . In the same cohort, the complete response rate after 104 weeks of chloraminophen alone was 78% (20/27) vs. 39% in patients with and without the t(11:18), respectively [85] .
However, there is no data available on pulmonary MALT lymphoma cases, despite the common presence of t(11:18) in this setting. Alternative therapies that have proven antitumoral effects are currently available, such as purine analogues (fludarabine; cladribine), pentostatin, NFκB inhibitor (bortezomib) or multiple-agent chemotherapy with chloraminophen/mitoxantrone/prednisone or bendamustine/rituximab [77, 86, 87] . However, the respective value of each treatment is difficult to estimate, particularly considering their side-effects [88] . Lenalidomide or bortezomib have also been evaluated, in second-line therapy [89] [90] [91] [92] [93] .
Finally, local therapy should be considered when feasible. Medical therapy must take into consideration age, symptoms, dissemination, and performance status, and a watch-and-wait attitude could potentially be the best solution. First line therapy actually mostly used is rituximab-chloraminophen therapy. However, one should consider the cost and the risk of hematological complications, giving chloraminophen alone as an option.
Conclusion
Significant progress has been made in identifying the oncogenic mechanisms involved in the development of pulmonary MALT lymphoma. No infectious agent has so far been isolated as the cause for pulmonary MALT lymphomas, which may play an equivalent role to H. pylori in the development of gastric MALT lymphomas. The diagnosis of clonal lymphoproliferative disease has also benefited from using immunohistochemistry and molecular biological techniques. The techniques' potential contribution should be more widely evaluated, in particular using bronchoscopic biopsy with small specimens, in order to avoid traumatic thoracotomy procedures that are at times performed purely for diagnostic purposes.
In the absence of randomized trials specifically focused on pulmonary MALT lymphoma, the same treatment is currently offered for all MALT lymphoma types, regardless of the localization. When there is other localization or respiratory contra-indications, surgery or radiotherapy should be considered. Otherwise chloraminophen-rituximab should be envisaged on a case-by-case basis, and in some instances, simply monitoring the patient may be the most appropriate approach. 
